Advanced search
Publication Cover
JAK-STAT Volume 2, 2013 - Issue 1
Journal homepage
4,803
Views
60
CrossRef citations to date
0
Altmetric
Review

STAT3 inhibitors for cancer therapy

Have all roads been explored?

Remi Fagard INSERM Unité 978; Bobigny, France; University Paris 13; UFR SMBH; Sorbonne Paris Cité; Bobigny, France; Biochimie Biologie Moléculaire; AP-HP; Hôpital Avicenne; Bobigny, FranceCorrespondence[email protected]
,
Valeri Metelev Moscow State University; Moscow, Russia
,
Inès Souissi INSERM Unité 978; Bobigny, France; University Paris 13; UFR SMBH; Sorbonne Paris Cité; Bobigny, France
&
Fanny Baran-Marszak INSERM Unité 978; Bobigny, France; University Paris 13; UFR SMBH; Sorbonne Paris Cité; Bobigny, France; Hématologie Biologique; AP-HP; Hôpital Avicenne; Bobigny, France
Article: e22882 | Published online: 01 Jan 2013

Citations (60)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Xiaolei Zhang, Tao Lu, Yanhui Ma, Rui Li, Yingxin Pang, Hongluan Mao & Peishu Liu. (2020) Novel Nanocomplexes Targeting STAT3 Demonstrate Promising Anti-Ovarian Cancer Effects in vivo. OncoTargets and Therapy 13, pages 5069-5082.
Read now
Rubashruti Kanna, Gaurav Choudhary, Nandini Ramachandra, Ulrich Steidl, Amit Verma & Aditi Shastri. (2018) STAT3 inhibition as a therapeutic strategy for leukemia. Leukemia & Lymphoma 59:9, pages 2068-2074.
Read now
Øystein Bruserud, Ina Nepstad, Michelle Hauge, Kimberley Joanne Hatfield & Håkon Reikvam. (2015) STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Review of Hematology 8:1, pages 29-41.
Read now
Pranabananda Dutta, Nafiseh Sabri, Jinghong Li & Willis X Li. (2014) Role of STAT3 in lung cancer. JAK-STAT 3:4.
Read now

Articles from other publishers (56)

Huma Rafiq, Junjian Hu, Mohammed Ageeli Hakami, Ali Hazazi, Mubarak A. Alamri, Hind A. Alkhatabi, Arif Mahmood, Bader S. Alotaibi, Abdul Wadood & Xiaoyun Huang. (2023) Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations. Scientific Reports 13:1.
Crossref
Irfan Yunianto, Margaret Currie, Kenny Chitcholtan & Peter Sykes. (2023) Potential drug repurposing of ruxolitinib to inhibit the JAK / STAT pathway for the treatment of patients with epithelial ovarian cancer . Journal of Obstetrics and Gynaecology Research 49:11, pages 2563-2574.
Crossref
Yushan Dong, Jingyu Chen, Yuhan Chen & Songjiang Liu. (2023) Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing. Biomedicine & Pharmacotherapy 167, pages 115513.
Crossref
Jiatao Song, Jiawei Wang, Sheng Tian & Huanqiu Li. (2023) Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives. Current Medicinal Chemistry 30:16, pages 1824-1847.
Crossref
Yu-Wei Wang, Li Lan, Min Wang, Jin-Yang Zhang, Yu-Hui Gao, Lei Shi & Li-Ping Sun. (2023) PROTACS: A technology with a gold rush-like atmosphere. European Journal of Medicinal Chemistry 247, pages 115037.
Crossref
Yanlei Guo & Shigang Ding. (2022) Helicobacter pylori Thioredoxin1 May Play a Highly Pathogenic Role via the IL6/STAT3 Pathway. Gastroenterology Research and Practice 2022, pages 1-10.
Crossref
A. A. Schegoleva, A. A. Khozyainova, T. S. Gerashchenko, L. D. Zhuikova & Evgeny V. Denisov. (2022) Metastasis prevention: targeting causes and roots. Clinical & Experimental Metastasis 39:4, pages 505-519.
Crossref
Acharya Balkrishna, Vallabh Prakash Mulay, Sudeep Verma, Jyotish Srivastava, Savita Lochab & Anurag Varshney. (2022) Penta-O-Galloyl-β-D-Glucose in Pistacia integerrima Targets AMPK-ULK1 and ERK/STAT3 Signaling Axes to Induce ROS-Independent Autophagic Cell Death in Human Lung Cancer Cells. Frontiers in Pharmacology 13.
Crossref
Andrea Spallarossa, Bruno Tasso, Eleonora Russo, Carla Villa & Chiara Brullo. (2022) The Development of FAK Inhibitors: A Five-Year Update. International Journal of Molecular Sciences 23:12, pages 6381.
Crossref
Lisa N. Heppler, Sanaz Attarha, Rosanne Persaud, Jennifer I. Brown, Peng Wang, Boryana Petrova, Isidora Tošić, Foster B. Burton, Yael Flamand, Sarah R. Walker, Jennifer E. Yeh, Roman A. Zubarev, Massimiliano Gaetani, Naama Kanarek, Brent D.G. Page & David A. Frank. (2022) The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase. Journal of Biological Chemistry 298:2, pages 101531.
Crossref
Tong Niu, Weiwei Zhang & Wei Xiao. (2021) MicroRNA regulation of cancer stem cells in the pathogenesis of breast cancer. Cancer Cell International 21:1.
Crossref
Matthias Kieslinger, Alexander Swoboda, Nina Kramer, Patricia Freund, Barbara Pratscher, Heidi A. Neubauer, Ralf Steinborn, Birgitt Wolfesberger, Andrea Fuchs-Baumgartinger, Richard Moriggl & Iwan A. Burgener. (2021) A Recurrent STAT5BN642H Driver Mutation in Feline Alimentary T Cell Lymphoma. Cancers 13:20, pages 5238.
Crossref
Zhaoyun Liu, Mei Han, Nanhao Meng, Jingyi Luo & Rong Fu. (2021) lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma. Oxidative Medicine and Cellular Longevity 2021, pages 1-18.
Crossref
Alice H. Grant, Armando EstradaIIIIII, Yoshira M. Ayala-Marin, America Y. Alvidrez-Camacho, Georgialina Rodriguez, Elisa Robles-Escajeda, Denisse A. Cadena-Medina, Alejandro C. Rodriguez & Robert A. Kirken. (2021) The Many Faces of JAKs and STATs Within the COVID-19 Storm. Frontiers in Immunology 12.
Crossref
Kusal T.G. Samarasinghe & Craig M. Crews. (2021) Targeted protein degradation: A promise for undruggable proteins. Cell Chemical Biology 28:7, pages 934-951.
Crossref
Muhamad Mustafa, Gamal El-Din A. Abuo-Rahma, Amer Ali Abd El-Hafeez, Esam R. Ahmed, Dalia Abdelhamid, Pradipta Ghosh & Alaa M. Hayallah. (2021) Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton. Bioorganic & Medicinal Chemistry Letters 40, pages 127965.
Crossref
Ting Peng, Orawan Wonganan, Zhonghui Zhang, Jialing Yu, Ruiying Xi, Yu Cao, Apichart Suksamrarn, Guolin Zhang & Fei Wang. (2021) A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase. International Journal of Molecular Sciences 22:7, pages 3354.
Crossref
Zita G. Ríos-Malváez, Ma-Angeles Cano-Herrera, Juan Carlos Dávila-Becerril, Gustavo Mondragón-Solórzano, María Teresa Ramírez-Apan, David Morales-Morales, Joaquín Barroso-Flores, Jonnathan G. Santillán-Benítez, M.V. Basavanag Unnamatla, Marco Antonio García-Eleno, Nelly González-Rivas & Erick Cuevas-Yañez. (2021) Synthesis, characterization and cytotoxic activity evaluation of 4-(1,2,3-triazol-1-yl) salicylic acid derivatives. Journal of Molecular Structure 1225, pages 129149.
Crossref
Marina R. Tavares, Klára Hrabánková, Rafał Konefał, Martin Kaňa, Blanka Říhová, Tomáš Etrych, Milada Šírová & Petr Chytil. (2021) HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy. Pharmaceutics 13:2, pages 179.
Crossref
Siphokazi Sinethemba Mtwebana & Earl Prinsloo. (2020) The commercially available STAT3 inhibitor 5,15-diphenylporphyrin (5,15-DPP) does not directly interact with STAT3 core residues 127–722. BMC Research Notes 13:1.
Crossref
Anna Jaśkiewicz, Tomasz Domoradzki & Beata Pająk. (2020) Targeting the JAK2/STAT3 Pathway—Can We Compare It to the Two Faces of the God Janus?. International Journal of Molecular Sciences 21:21, pages 8261.
Crossref
Aliaa M. Mohassab, Heba A. Hassan, Dalia Abdelhamid & Mohamed Abdel-Aziz. (2020) STAT3 transcription factor as target for anti-cancer therapy. Pharmacological Reports 72:5, pages 1101-1124.
Crossref
Zhi‐Hua Liu, Mei‐Ling Chen, Qi Zhang, Yu Zhang, Xin An, Yi‐Ling Luo, Xue‐Min Liu, Shang‐Xin Liu, Qian Liu, Ting Yang, Yan‐Min Liu, Bin‐Liu Liu, Ai‐Jun Zhou, Man‐Zhi Li, Yu‐Jie Liu, Ze‐Xian Liu & Qian Zhong. (2020) ZIC2 is downregulated and represses tumor growth via the regulation of STAT3 in breast cancer . International Journal of Cancer 147:2, pages 505-518.
Crossref
Jan Jamroskovic, Mara Doimo, Karam Chand, Ikenna Obi, Rajendra Kumar, Kristoffer Brännström, Mattias Hedenström, Rabindra Nath Das, Almaz Akhunzianov, Marco Deiana, Kazutoshi Kasho, Sebastian Sulis Sato, Parham L. Pourbozorgi, James E. Mason, Paolo Medini, Daniel Öhlund, Sjoerd Wanrooij, Erik Chorell & Nasim Sabouri. (2020) Quinazoline Ligands Induce Cancer Cell Death through Selective STAT3 Inhibition and G-Quadruplex Stabilization. Journal of the American Chemical Society 142:6, pages 2876-2888.
Crossref
Büsra Öztürk Akcora, Alexandros Vassilios Gabriël, Ana Ortiz‐Perez & Ruchi Bansal. (2020) Pharmacological inhibition of STAT3 pathway ameliorates acute liver injury in vivo via inactivation of inflammatory macrophages and hepatic stellate cells. FASEB BioAdvances 2:2, pages 77-89.
Crossref
Po-Chang Shih. (2020) Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains. Life Sciences 242, pages 117241.
Crossref
Siva Koganti, Sandeepta Burgula & Sumita Bhaduri-McIntosh. (2020) STAT3 activates the anti-apoptotic form of caspase 9 in oncovirus-infected B lymphocytes. Virology 540, pages 160-164.
Crossref
Matthias Kieslinger, Alexander Swoboda, Nina Kramer, Barbara Pratscher, Birgitt Wolfesberger & Iwan A. Burgener. (2019) Companion Animals as Models for Inhibition of STAT3 and STAT5. Cancers 11:12, pages 2035.
Crossref
Parisa Zafari, Alireza Rafiei, Seyed‐Alireza Esmaeili, Mohammadreza Moonesi & Mahdi Taghadosi. (2019) Survivin a pivotal antiapoptotic protein in rheumatoid arthritis. Journal of Cellular Physiology 234:12, pages 21575-21587.
Crossref
Sabrina Ernst & Gerhard Müller-Newen. (2019) Nucleocytoplasmic Shuttling of STATs. A Target for Intervention?. Cancers 11:11, pages 1815.
Crossref
Yue-Ting K. Lau, Malini Ramaiyer, Daniel E. Johnson & Jennifer R. Grandis. (2019) Targeting STAT3 in Cancer with Nucleotide Therapeutics. Cancers 11:11, pages 1681.
Crossref
Arianna Gelain, Matteo Mori, Fiorella Meneghetti & Stefania Villa. (2019) Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents. Current Medicinal Chemistry 26:27, pages 5165-5206.
Crossref
Yang Sheng Hu, Xu Han & Xin Hua Liu. (2019) STAT3: A Potential Drug Target for Tumor and Inflammation. Current Topics in Medicinal Chemistry 19:15, pages 1305-1317.
Crossref
Roberta Santarelli, Valentina Carillo, Maria Anele Romeo, Aurelia Gaeta, Cristina Nazzari, Roberta Gonnella, Marisa Granato, Gabriella D’Orazi, Alberto Faggioni & Mara Cirone. (2019) STAT3 phosphorylation affects p53/p21 axis and KSHV lytic cycle activation. Virology 528, pages 137-143.
Crossref
Loukik Arora, Alan Kumar, Frank Arfuso, Wee Chng & Gautam Sethi. (2018) The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers 10:9, pages 327.
Crossref
Christian Njatcha, Mariya Farooqui, Adam Kornberg, Daniel E. Johnson, Jennifer R. Grandis & Jill M. Siegfried. (2018) STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics 17:9, pages 1917-1926.
Crossref
Po-Chang Shih, Yiwen Yang, Gary N. Parkinson, Andrew Wilderspin & Geoffrey Wells. (2018) A high-throughput fluorescence polarization assay for discovering inhibitors targeting the DNA-binding domain of signal transducer and activator of transcription 3 (STAT3). Oncotarget 9:66, pages 32690-32701.
Crossref
Lisley I. Mambelli, Sarah F. Teixeira, Salomão D. Jorge, Bárbara Kawamura, Renato Meneguelo, José A.M. Barbuto, Ricardo A. de Azevedo & Adilson K. Ferreira. (2018) Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model. Biomedicine & Pharmacotherapy 103, pages 18-28.
Crossref
Sara Verdura, Elisabet Cuyàs, Laura Llorach-Parés, Almudena Pérez-Sánchez, Vicente Micol, Alfons Nonell-Canals, Jorge Joven, Manuel Valiente, Melchor Sánchez-Martínez, Joaquim Bosch-Barrera & Javier A. Menendez. (2018) Silibinin is a direct inhibitor of STAT3. Food and Chemical Toxicology 116, pages 161-172.
Crossref
Jacopo Sgrignani, Maura Garofalo, Milos Matkovic, Jessica Merulla, Carlo V. Catapano & Andrea Cavalli. (2018) Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development. International Journal of Molecular Sciences 19:6, pages 1591.
Crossref
Mingyue Li, Grace Gar-Lee Yue, Li-Hua Song, Mao-Bo Huang, Julia Kin-Ming Lee, Stephen Kwok-Wing Tsui, Kwok-Pui Fung, Ning-Hua Tan & Clara Bik-San Lau. (2018) Natural small molecule bigelovin suppresses orthotopic colorectal tumor growth and inhibits colorectal cancer metastasis via IL6/STAT3 pathway. Biochemical Pharmacology 150, pages 191-201.
Crossref
Hamidreza Ebrahimiyan, Saeed Aslani, Nima Rezaei, Ahmadreza Jamshidi & Mahdi Mahmoudi. (2018) Survivin and autoimmunity; the ins and outs. Immunology Letters 193, pages 14-24.
Crossref
Kyohei Nakamura & Mark J Smyth. (2017) Targeting cancer‐related inflammation in the era of immunotherapy. Immunology & Cell Biology 95:4, pages 325-332.
Crossref
Youn Choi, Junseong Kim, Kang Lee, Yu-Jeong Choi, Bo-Ram Ye, Min-Sun Kim, Seong-Gyu Ko, Seung-Hong Lee, Do-Hyung Kang & Soo-Jin Heo. (2017) Tuberatolide B Suppresses Cancer Progression by Promoting ROS-Mediated Inhibition of STAT3 Signaling. Marine Drugs 15:3, pages 55.
Crossref
Antons Martincuks, Dirk Fahrenkamp, Serge Haan, Andreas Herrmann, Andrea Küster & Gerhard Müller-Newen. (2016) Dissecting functions of the N-terminal domain and GAS-site recognition in STAT3 nuclear trafficking. Cellular Signalling 28:8, pages 810-825.
Crossref
Jennifer E. Yeh & David A. Frank. (2016) STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy. ChemMedChem 11:8, pages 795-801.
Crossref
Qifang ZhangDewan Md Sakib HossainPriyanka DuttaguptaDayson MoreiraXingli ZhaoHaejung WonRalf BuettnerSergey NechaevMarcin MajkaBin Zhang, Qi CaiPiotr Swiderski, Ya-Huei Kuo, Stephen FormanGuido Marcucci & Marcin Kortylewski. (2016) Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 127:13, pages 1687-1700.
Crossref
Susan Sammak & Giovanna Zinzalla. (2015) Targeting protein–protein interactions (PPIs) of transcription factors: Challenges of intrinsically disordered proteins (IDPs) and regions (IDRs). Progress in Biophysics and Molecular Biology 119:1, pages 41-46.
Crossref
Camilla Pilati & Jessica Zucman-Rossi. (2015) Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine & Growth Factor Reviews 26:5, pages 499-506.
Crossref
Mona Doshi, Alicja Copik & Andre J. Gesquiere. (2015) Development and characterization of conducting polymer nanoparticles for photodynamic therapy in vitro. Photodiagnosis and Photodynamic Therapy 12:3, pages 476-489.
Crossref
Anna Czerwoniec, Malgorzata Szelag, Kajetan Juszczak, Joanna Wesoly & Hans A.R. Bluyssen. (2015) CAVS—Novel in silico selection strategy of specific STAT inhibitory compounds. Journal of Computational Science 10, pages 186-194.
Crossref
Joaquim Bosch-Barrera & Javier A. Menendez. (2015) Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treatment Reviews 41:6, pages 540-546.
Crossref
Øystein Bruserud, Håkon Reikvam, Hanne Fredly, Jørn Skavland, Karen-Marie Hagen, Tuyen Thy van Hoang, Annette K. Brenner, Amir Kadi, Audrey Astori, Bjørn Tore Gjertsen & Frederic Pendino. (2014) Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. Oncotarget 6:5, pages 2794-2811.
Crossref
Carmen Avendaño & J. Carlos Menéndez. 2015. Medicinal Chemistry of Anticancer Drugs. Medicinal Chemistry of Anticancer Drugs 391 491 .
Peng Zhou, Gang Huang, Yuanyin Zhao, Dan Zhong, Zhizhen Xu, Yijun Zeng, Yan Zhang, Song Li & Fengtian He. (2014) MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. Cellular Signalling 26:6, pages 1347-1354.
Crossref
Eva Putz, Maria Hoelzl, Julia Baeck, Zsuzsanna Bago-Horvath, Christian Schuster, Brian Reichholf, Daniela Kern, Fritz Aberger, Veronika Sexl & Andrea Hoelbl-Kovacic. (2014) Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers 6:1, pages 193-210.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.